ホーム>>Virodhamine trifluoroacetate

Virodhamine trifluoroacetate

カタログ番号GC50155

内因性カンナビノイド受容体の混合アゴニスト/アンタゴニストであるバイロダミンのTFA塩

Products are for research use only. Not for human use. We do not sell to patients.

Virodhamine trifluoroacetate 化学構造

Cas No.: 1415264-56-0

サイズ 価格 在庫数 個数
10 mg
$272.00
在庫あり
50 mg
$1,142.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com


顧客レビュー

カスタマーレビューに基づきます。

Sample solution is provided at 25 µL, 10mM.

Description of Virodhamine trifluoroacetate

TFA salt of virodhamine, an endogenous cannabinoid receptor mixed agonist/antagonist that is found in higher concentrations peripherally than anandamide. Virodhamine is a full agonist at GPR55 and CB2 and partial agonist/antagonist at CB1 (EC50 values are 12, 381 and 2920 nM at GPR55, CB2 and CB1 receptors respectively).

Porter et al (2002) Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J.Pharmacol.Exp.Ther. 301 1020 PMID:12023533

Chemical Properties of Virodhamine trifluoroacetate

Cas No. 1415264-56-0 SDF
Canonical SMILES O=C(OCCN)CCC\C=C/C\C=C/C/C=C\C/C=C\CCCCC.FC(F)(F)C(O)=O
Formula C22H37NO2.CF3CO2H M.Wt 461.56
溶解度 Soluble in DMSO Storage Store at -20°C
General tips Please select the appropriate solvent to prepare the stock solution according to the solubility of the product in different solvents; once the solution is prepared, please store it in separate packages to avoid product failure caused by repeated freezing and thawing.Storage method and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored at -20°C, please use it within 1 month.
To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time.
Shipping Condition Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request.

Complete Stock Solution Preparation Table of Virodhamine trifluoroacetate

Prepare stock solution
1 mg 5 mg 10 mg
1 mM 2.1666 mL 10.8328 mL 21.6657 mL
5 mM 433.3 μL 2.1666 mL 4.3331 mL
10 mM 216.7 μL 1.0833 mL 2.1666 mL
  • モルアリティ計算機

  • 希釈計算機

  • Molecular Weight Calculator

質量
=
濃度
x
容積
x
MW*
 
 
 
**ストックソリューションを準備する際には、常にバイアルラベルおよび MSDS/CoA(オンラインで利用可能)で掲載された製品のロット固有分子量を使用してください。

計算

In vivo Formulation Calculator (Clear solution) of Virodhamine trifluoroacetate

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.

Product Documents

Quality Control & SDS

View current batch:

レビュー

Review for Virodhamine trifluoroacetate

Average Rating: 5 ★★★★★ (Based on Reviews and 18 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Virodhamine trifluoroacetate

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.